A Comparison of Glucose and Additional Signals for Three Different Exercise Types in Adolescents with Type 1 Diabetes Using a Hybrid Closed-Loop System
<b><i>Objective:</i></b> To compare glycemic outcomes during and following moderate-intensity exercise (MIE), high-intensity interval exercise (HIE), and resistance exercise (RE) in adolescents with type 1 diabetes (T1D) using a hybrid closed-loop (HCL) insulin pump while measuring additional physiological signals associated with activity. <b><i>Methods:</i></b> Twenty-eight adolescents (average age 16.3 ± 2.1 years, 50% females, average duration of T1D 9.4 ± 4 years) using HCL (Medtronic MiniMed 670G) undertook 40 min of MIE, HIE, and RE. A temporary glucose target (8.3 mmol/L, 150 mg/dL) was set for 2 h prior and during exercise. Heart rate, accelerometer, venous glucose, lactate, ketones, and counter-regulatory hormones were measured for 280 min postexercise commencement. The primary outcome was glucose percentage time in range (TIR): 3.9-10 mmol/L (70-180 mg/dL) for 14 h from exercise onset. <b><i>Results:</i></b> Median (interquartile range) TIR for HIE was 88 (78, 96)%, MIE 79 (63, 88)%, and RE 86 (72, 95)% for 14 h from exercise onset. For MIE compared with HIE, TIR was lower (<i>P</i> = 0.012) and time above range (TAR) was greater (18 [2.4, 28] vs. 6.9 [0.0, 14]%, <i>P</i> = 0.041). Hypoglycemia occurred in 13 (46%), 11 (39%), and 14 (50%) of participants for HIE, MIE, and RE, respectively, the majority following the meal after exercise. There were higher levels of lactate (<i>P</i> = 0.001), growth hormone (<i>P</i> = 0.001), noradrenaline (<i>P</i> = 0.001), and heart rate (<i>P</i> = 0.01) during HIE and RE compared with MIE. <b><i>Conclusions</i></b>: HCL use in adolescents with T1D results in excellent TIR during different forms of exercise when a temporary target is set 2 h before. Extending the temporary target after exercise may also be needed to help minimize postexercise hypoglycemia.
Authors
- JL Gooley
- Varuni Obeyesekere
- Rowen Seckold (ORCID: https://orcid.org/0000-0003-3903-3988)
- Carmel E. Smart (ORCID: https://orcid.org/0000-0003-3104-8800)
- Sara Vogrin (ORCID: https://orcid.org/0000-0002-1597-9421)
- Dale Morrison (ORCID: https://orcid.org/0000-0002-3613-4946)
- Jordan Rafferty
- Barbora Paldus (ORCID: https://orcid.org/0000-0002-4303-0125)
- David Norman O'Neal (ORCID: https://orcid.org/0000-0002-0870-4032)
- Sarah R. Valkenborghs (ORCID: https://orcid.org/0000-0003-2259-4682)
- Bruce R. King (ORCID: https://orcid.org/0000-0002-8958-7404)
- Dessi P. Zaharieva (ORCID: https://orcid.org/0000-0002-9374-8469)
- Michael Charles Riddell (ORCID: https://orcid.org/0000-0001-6556-7559)
Institutions
- The University of Melbourne (AU)
- York University (CA)
- Diabetes Australia (AU)
- St Vincent's Hospital Melbourne (AU)
- Hunter Medical Research Institute (AU)
- John Hunter Children's Hospital (AU)
- University of Newcastle Australia (AU)
- Stanford University (US)
Publication Details
- Journal
- Diabetes Technology & Therapeutics
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1089/dia.2024.0254
- Citations
- 3
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.88